YM155 (Sepantronium Bromide)

Catalog No.S1130

YM155 (Sepantronium Bromide) Chemical Structure

Molecular Weight(MW): 443.29

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 77 Publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 M1K4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX0fHJoPzJiaB?= NXTncG9qTE2VTx?= NHK3b2tKSzVyPUCuNFA6KMLzIECuNFAxQSEQvF2= MkGwNlU3PTl5M{G=
M-07e M4Dh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nufFczKGh? MofHSG1UVw>? M3TBe2lEPTB;MD6wOFAhyrFiMD6wNVMh|ryP M{jzW|I2PjV7N{Ox
THP-1 M{XMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGxSXY4OiCq M3vGSmROW09? NEfmeXpKSzVyPUCuNFUyKMLzIECuNFE{KM7:TR?= MYWyOVY2QTd|MR?=
CMK NFuyUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj0O|IhcA>? M1vheGROW09? MmXNTWM2OD1yLkC1N{DDuSByLkCwPUDPxE1? MV2yOVY2QTd|MR?=
MV4-11 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWC3NkBp MUHEUXNQ Mmq5TWM2OD1yLkC1OUDDuSByLkCyPEDPxE1? NFjQXFYzPTZ3OUezNS=>
AML-193 NVy5PWs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF23[WY4OiCq NXyxUoZ1TE2VTx?= M{LvU2lEPTB;MD60OlIhyrFiMD6wOlAh|ryP NECxOG8zPTZ3OUezNS=>
HL-60 M4fmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HyNlczKGh? NHrtXIpFVVOR M4\hVmlEPTB;MD6wNFEhyrFiMD6wNFAzKM7:TR?= Mki3NlU3PTl5M{G=
ML-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUW3NkBp NFnafWRFVVOR MXXJR|UxRTBwMEC5JOKyKDBwMECyJO69VQ>? NGfYZ|gzPTZ3OUezNS=>
OCI/AML3 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX63NkBp M3XrTGROW09? NX7Ud3NPUUN3ME2wMlAyOSEEsTCwMlAxOiEQvF2= MlLzNlU3PTl5M{G=
HEL NInXVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq2UFd{PzJiaB?= M2fxXWROW09? MnjTTWM2OD1yLkW1PUDDuSByLkCzPEDPxE1? NVLxPWN3OjV4NUm3N|E>
ME-1 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzafFZ7PzJiaB?= M3faPWROW09? NH;LW29KSzVyPUCuOlg1KMLzIECuNVc6KM7:TR?= NUnjcVF2OjV4NUm3N|E>
THP-1 NUewVWlvSXCxcITvd4l{KEG|c3H5 NFTQPZAyyqEQvF2= NIn6TlE4OiCq M3O2PWROW09? NFvPRY1qdmS3Y3XzJIFxd3C2b4Ppdy=> NYTHWFRHOjV4NUm3N|E>
M-07e M1\JfGZ2dmO2aX;uJGF{e2G7 MonLNQKBmzIEoN88US=> M1O5W|czKGh? NVP1W21LTE2VTx?= NFuxUGxqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu NEHp[ZozPTZ3OUezNS=>
THP-1 MWHGeY5kfGmxbjDBd5NigQ>? NF;4VYwx6oDVMdMg{txO MWq3NkBp Mon5SG1UVw>? MX\pcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw MnjtNlU3PTl5M{G=
CMK NGC3Wo1HfW6ldHnvckBCe3OjeR?= NHLPZnEx6oDVMdMg{txO M{DmfVczKGh? MlriSG1UVw>? NXfCRo9pcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> NX7xOXBuOjV4NUm3N|E>
AML-193 NFvzXJNHfW6ldHnvckBCe3OjeR?= M4j0NFDjiJNzwrFOwG0> NVnNVZV[PzJiaB?= NIfWXoxFVVOR NVLFbWhzcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MkOzNlU3PTl5M{G=
Kasumi-1 MoC0SpVv[3Srb36gRZN{[Xl? MW[w5qCUOcLizszN MnXCO|IhcA>? M1ztSmROW09? NVXkUnVycW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> NFH5[I8zPTZ3OUezNS=>
MV4-11 NELoU5hHfW6ldHnvckBCe3OjeR?= M1vycFDjiJNzwrFOwG0> M3r0OFczKGh? NEO5N|NFVVOR MXzpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NF7PXW4zPTZ3OUezNS=>
MUG-Chor  MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK3epZ7OC13IN88US=> MU[yOE81QCCq NEf0fVJKSzVyPUeuNFXjiImwTTDmc5IhPDiq MkLvNlU3PDBzOEW=
U-CH1  MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOwMVUh|ryP MlLrNlQwPDhiaB?= MUDJR|UxRTlwMERihKlvVSCob4KgOFhp NF\pXVEzPTZ2MEG4OS=>
KATOIII NWH3dGNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrqfosyOC9{MDDuUS=> NX30T3VGPDhiaB?= Mlq5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MW[yOVY{PTB3NR?=
AGS  NFTaWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTYfIEzOTBxMkCgcm0> MmHCOFghcA>? M3XxRYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnP5NlU3OzVyNUW=
SACC-83 NWTZNZFiTnWwY4Tpc44hSXO|YYm= MUm1JI5O M{HmblQ5KGh? M2\UbIRm[3KnYYPld{BvfWOuZXHyJIV5eHKnc4Ppc44hd2ZiSFnGMVHPuQ>? NIDsS3QzPTR6NU[zOS=>
INA-6 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDxfYsxNTVyMDDuUS=> NY\iWGpjPDhiaB?= M3\WRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mn7WNlUzQTZ7N{i=
U-266 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv1cpIxNTVyMDDuUS=> MWO0PEBp NXvGeXJucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4TZelI2Ojl4OUe4
MOLP-8 M3H6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\qUZpNOC13MECgcm0> NIjSTVU1QCCq NHrwW2xqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{DweVI2Ojl4OUe4
HG-1 MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljKNE02ODBibl2= NGe4SXo1QCCq MnnObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmWyNlUzQTZ7N{i=
NCI-H929 NHzyWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;SOohVOC13MECgcm0> MVm0PEBp NEXJPFlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIT3WYczPTJ7Nkm3PC=>
OPM-2 NF7jVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTpVW0xNTVyMDDuUS=> MVe0PEBp NWrXWmN6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGDCUXMzPTJ7Nkm3PC=>
L-363 NX;uZ|BwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zYblAuPTByIH7N NHLJUY81QCCq MlzCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3e1RlI2Ojl4OUe4
MOLP-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmwemhUOC13MECgcm0> NFHaSWY1QCCq M2i2O4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2TsTlI2Ojl4OUe4
KMS-12-BM NV3sTndxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfyeYloOC13MECgcm0> M3;oO|Q5KGh? NYS3W5c{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFPqfYwzPTJ7Nkm3PC=>
SK-MM-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rMbFAuPTByIH7N MVO0PEBp Ml\GbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWe5fFBzOjV{OU[5O|g>
U-266 MXrBdI9xfG:|aYOgRZN{[Xl? NGfleGQxNTVyIH7N NH\wW2gzPCCq M4TVNolv\HWlZYOgZZBweHSxc3nz MXyyOVI6Pjl5OB?=
INA-6  M2jHc2Fxd3C2b4Ppd{BCe3OjeR?= M13r[lAuPTBibl2= NEn2Z2QzPCCq NXPMO4VncW6mdXPld{BieG:ydH;zbZM> NFnnPHczPTJ7Nkm3PC=>
MCF7 M3y5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXy3NkBp Ml[0TWM2OD1zMzFCtUA3KG6P NHrGVWEzPTJ{MEKyOS=>
MCF7-TamR6 NEOzPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvkbG44OiCq MVjJR|UxRThiwsGgOkBvVQ>? M3X1UVI2OjJyMkK1
MCF7-TamR7 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPSc5Q4OiCq NF62ZXdKSzVyPUigxtEhOyCwTR?= NXTRTmVROjV{MkCyNlU>
MCF7-TamR8 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DKS|czKGh? MUnJR|UxRTF3INMxJFYhdk1? MmLnNlUzOjB{MkW=
MCF7-TamC3 NH;E[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rJOFczKGh? M2HK[mlEPTB;NjFCtUA{KG6P MVuyOVIzODJ{NR?=
MCF7-TamC6 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3aUIY4OiCq NVrZNJBlUUN3ME22JOKyKDBwMTDuUS=> NHz0UVAzPTJ{MEKyOS=>
MDA-MB-231 NWn1Z5M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[3NkBp M4LHWWlEPTB;NTFCtUAyKG6P M1nadlI2OjJyMkK1
SK-BR-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7tfW9sPzJiaB?= MVPJR|UxRTdiwsGgNE4{KG6P M1T5dVI2OjJyMkK1
Eca109 MnLCSpVv[3Srb36gRZN{[Xl? NFO0ZW8yNTVyIH7N M{PMelQ5KGh? NIDxSpFFVVOR M4r6[5N2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NIT3TGkzPTF|OUO5OS=>
TE13 NXnvTGZ5TnWwY4Tpc44hSXO|YYm= MVKxMVUxKG6P NV\uTnc6PDhiaB?= MX3EUXNQ M1rFOpN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NXT4OYZLOjVzM{mzPVU>
Eca109 NXPhS5hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTwSld[OC1zMECgcm0> NWO2NWtOOjRxNEigbC=> NWTxRZRTTE2VTx?= MX;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Ml[1NlUyOzl|OUW=
TE13 M2LFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7NNIExNTFyMDDuUS=> NWjZc41SOjRxNEigbC=> NXy0RVByTE2VTx?= M1\afYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mn3ZNlUyOzl|OUW=
MT-3 M1f2WWtqdmG|ZTDBd5NigQ>? NYSyRm5oPzJiaB?= MmHXSG1UVw>? NXXuNGRSUUN3ME2yMlg3KMLzIECuOVQhdk1iZn;yJGRTPCCneIDy[ZN{cW:w M3z0flI1QDZ4NUi1
MDA-MB-468 MYrLbY5ie2ViQYPzZZk> M3W1UlczKGh? M{GxRmROW09? NH7idpFKSzVyPUCuNVEhyrFiMD6wNUBvVSCob4KgSHI1KGW6cILld5Nqd25? NHjkWmwzPDh4NkW4OS=>
SUM-159 MVHLbY5ie2ViQYPzZZk> M2\wflczKGh? Mnm2SG1UVw>? NUnVWGlzUUN3ME2xMlczKMLzIECuN|Mhdk1iZn;yJGRTPCCneIDy[ZN{cW:w M2K1Z|I1QDZ4NUi1
MT-3 M3T2U2tqdmG|ZTDBd5NigQ>? M1fjOlczKGh? NXLYR2VLTE2VTx?= MY\JR|UxRTV2LkGxJOKyKDRwM{Kgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v NWjHbY5HOjR6Nk[1PFU>
MDA-MB-468 M4PsVWtqdmG|ZTDBd5NigQ>? M1jqVVczKGh? NWnY[FdLTE2VTx?= NETDVZZKSzVyPUCuNFchyrFiMD6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? M3\tUFI1QDZ4NUi1
SUM-159 M3viSWtqdmG|ZTDBd5NigQ>? M2DhR|czKGh? MnrwSG1UVw>? NXGwS5Q4UUN3ME22PU41KMLzIESuNlMhdk1iZn;yJGRTPSCneIDy[ZN{cW:w M2X3ZVI1QDZ4NUi1
MT-3 + NAC MYLLbY5ie2ViQYPzZZk> MYO3NkBp MWLEUXNQ MoL3TWM2OD13Nj6yJOKyKDJwMEegcm0h\m:{IFTSOUBmgHC{ZYPzbY9v NUTPWoNyOjR6Nk[1PFU>
MT-3 + SB203580 MY\LbY5ie2ViQYPzZZk> MVy3NkBp M1rOVmROW09? NIq2UGhKSzVyPUO4MlQyKMLzIEWuNFIhdk1iZn;yJGRTPSCneIDy[ZN{cW:w M1X1TVI1QDZ4NUi1
DB Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPiNVAhdk1? NUn0dmZnOjRiaB?= NXHsTm17TE2VTx?= MX3pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= MYSyOFQ5PjV7NR?=
SU-DHL-8 M1LrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLJNVAhdk1? M37BfFI1KGh? M{fSZ2ROW09? NFHRTm9qdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> NXLCelBJOjR2OE[1PVU>
WSU-DLCL2 M33mTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGxNEBvVQ>? NEX5bVEzPCCq M1jr[GROW09? NGX1XJVqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> NGq3O4czPDR6NkW5OS=>
ACC-2 NFnOZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjyeGQxNTFyMDDuUS=> NEnq[44zPCCq MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3mzRVI1OzdyOUm1
ACC-2 NWLnPWg3SXCxcITvd4l{KEG|c3H5 M3rQeFAuOjBibl2= NIrhUWozPCCq MmDkbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFniT3IzPDN5MEm5OS=>
ACC-2 NIqxUHZHfW6ldHnvckBCe3OjeR?= MnzONE0zOCCwTR?= NI\rRZYzPCCq M2XpWYlv[3KnYYPld{B1cGViY3;ueoVze2mxbjDv[kBNSzOLIITvJGxEO0mL M1\3NlI1OzdyOUm1
BFTC905 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:0RlAuOTByMDDuUS=> MnPoOFghcMLi NF\abmRFVVOR M1jXcmlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkW2NlQzQTd4NES=
T24 NWLZRoNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMVExODBibl2= Mnz3OFghcMLi M1rucGROW09? M2Hi[mlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MY[yOFI6PzZ2NB?=
TSGH8301  MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PG[VAuOTByMDDuUS=> NXHZVplEPDhiaNMg MnPYSG1UVw>? MknlTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYHs[WRMOjR{OUe2OFQ>
BFTC909 M4i5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPjS5h4OC1zMECwJI5O NUja[5hlPDhiaNMg MoPqSG1UVw>? MX;JR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn6zNlQzQTd4NES=
BFTC905 NETZfJFCeG:ydH;zbZMhSXO|YYm= MkC1NlAhdk1? M3LqV|Q5KGh? NX:zb5ZRTE2VTx?= MlT6bY5lfWOnczDhdI9xfG:|aYO= MVSyOFI6PzZ2NB?=
BFTC905 MmHaSpVv[3Srb36gRZN{[Xl? NX3vXZhGOjBibl2= NETaSFA1QCCq MXvEUXNQ NYPUepVw\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEyFM1KtTWk> MnzzNlQzQTd4NES=
A2780p NXfmUYlLTnWwY4Tpc44hSXO|YYm= NHLWWYMxNTFyMDDuUS=> M4WyN|I1KGh? M2j4XmROW09? NXu1fmcxcW6mdXPld{BUfXK4aY\pckBld3ewcnXneYxifGmxbtMg NH7xSY4zPDJ4Mki3OS=>
A2780cis M1rOfWZ2dmO2aX;uJGF{e2G7 MlP0NE0yODBibl2= M2\hflI1KGh? NX7nSG5FTE2VTx?= M1rORYlv\HWlZYOgV5Vzfmm4aX6g[I94dnKnZ4XsZZRqd28EoB?= NGPvTW4zPDJ4Mki3OS=>
A2780p MlzJRZBweHSxc3nzJGF{e2G7 NGW4Spc2NTFyMDDuUS=> M2TqdVI1NzR6IHi= NVXzcYFqTE2VTx?= MY\pcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy NEP2O4kzPDJ4Mki3OS=>
A2780cis M3rISWFxd3C2b4Ppd{BCe3OjeR?= MWi1MVExOCCwTR?= MX2yOE81QCCq NGrocGNFVVOR M4XVSYlv[3KnYYPld{BieG:ydH;zbZMhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MV6yOFI3Ojh5NR?=
SH-SY5Y NE[0eYhCeG:ydH;zbZMhSXO|YYm= MnzHNU8yOC9zMECgxtVO M1TQdFczKGh? M3fKd2ROW09? NIe4NIxqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXmyO3pGOjR{NUS1OlA>
HL-60 NGXIfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13PZlczyqCq M{\m[mROW09? NIfNcppKSzVyPUCuN{BvVQ>? NXvBeWVKOjN4MUi4OlI>
U937  NF;TUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX5[Vg4OsLiaB?= MYjEUXNQ NXf0UYdbUUN3ME2wMlghdk1? NGm5W4YzOzZzOEi2Ni=>
HL-60  NX7XTFA4TnWwY4Tpc44hSXO|YYm= M2\oPVHDqM7:TR?= NYSwOFBbPi9zMj:yOEBp MWHEUXNQ MUjpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDzeZJ3cX[rbh?= Ml;DNlM3OTh6NkK=
U937  Mmn5SpVv[3Srb36gRZN{[Xl? NYTlO|YzOcLizszN NUfJbmpyPi9zMj:yOEBp NXzrR3ZyTE2VTx?= NGmzXHlqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=> M4r2dFI{PjF6OE[y
HL-60 MniwRZBweHSxc3nzJGF{e2G7 MViwMlEwOSEQvF2= MWq4JIg> NUGyRXVbTE2VTx?= M3q1eIlv\HWlZYOgZZBweHSxc3nz NFzJdGUzOzZzOEi2Ni=>
Sk-NEP-1  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofjNU0yODByMDDuUS=> NHvmfVEzPCCq MljXSG1UVw>? NUD2ZpdbUUN3ME2xNFAhdk1? MXqyN|I3PzZ7OR?=
SK-NEP-1  MoLZRZBweHSxc3nzJGF{e2G7 M3Kze|UxNzFyMDDuUS=> MnrFNVIwOjRiaB?= NGrzTlVFVVOR NYe5SXJncW6mdXPld{BieG:ydH;zbZM> NEOxcIEzOzJ4N{[5PS=>
TC-32 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnlNE4yNTFyMECgcm0> NHfDNHRGSzVyPUOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFzCS|IzOjl4MUe2Ny=>
TC-71 Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:4NE4yNTFyMECgcm0> NXTZTI5YTUN3ME21Mlchdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWCyNlk3OTd4Mx?=
SK-ES-1 NYXSWopVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSwMlEuOTByMDDuUS=> NUewU5ZoTUN3ME2yMlghdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3zsVVIzQTZzN{[z
RD-ES MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTZNE4yNTFyMECgcm0> Mn;XSWM2OD14LkKgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnXpNlI6PjF5NkO=
HEK293 NVTS[ZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXVeZkxNjFvMUCwNEBvVQ>? M4X2TWVEPTB;MkOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MV:yNlk3OTd4Mx?=
M059J M{X5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3ST|JpOC13MDDuUS=> M{DNS|Q5KGh? MkGwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlzQNlI4PzBzMUC=
M059K NV\mVoNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLCNE02OCCwTR?= NF:ydI01QCCq M3L3PYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnOzNlI4PzBzMUC=
M059J M{XlXmFxd3C2b4Ppd{BCe3OjeR?= NVf4doVCOzBibl2= M3\nWVI1KGh? NIXFd|lqdmS3Y3XzJIFxd3C2b4Ppdy=> M2frdVIzPzdyMUGw
M059K M3zLfWFxd3C2b4Ppd{BCe3OjeR?= M3znW|MxKG6P MWGyOEBp MWPpcoR2[2W|IHHwc5B1d3Orcx?= MXiyNlc4ODFzMB?=
PANC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfWWINvOC5yMT2xNFAxKG6P MnzWOFghcA>? M2niSWlEPTB;Mz62PUBvVQ>? NVq4N3BvOjJ5MkO4O|E>
MIAPaCa-2 NH;uWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTINE4xOS1zMECwJI5O NXXrS3dTPDhiaB?= NF63T5ZKSzVyPUK5MlM3KG6P NWTZSW9POjJ5MkO4O|E>
BxPC-3 NXu3RVQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm4NE4xOS1zMECwJI5O M3rUSFQ5KGh? M1fET2lEPTB;M{CuNlYhdk1? MYSyNlczOzh5MR?=
PANC-1 NV\qfWl3TnWwY4Tpc44hSXO|YYm= NFzsbG8xNTFyMECgcm0> MViyOEBp NYnaWZlScW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v NYXCeGhyOjJ5MkO4O|E>
MIAPaCa-2 M{P6emZ2dmO2aX;uJGF{e2G7 M1\QPVAuOTByMDDuUS=> MVKyOEBp MUPpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= MY[yNlczOzh5MR?=
BxPC-3 NUjPNm9QTnWwY4Tpc44hSXO|YYm= NE\tcWwxNTFyMECgcm0> NUXuPHlUOjRiaB?= NG[4[FZqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> M4nMTlIzPzJ|OEex
RPMI-7951 M2n6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlOxS2k2OD1|LkKgcm0> M{ewfVIyPzN5NUCy
SK-MEL-5 NFW1RYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInsd2lIUTVyPUSuNkBvVQ>? NVXzS2VWOjF5M{e1NFI>
A375 NVqwc2tDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzkOoJkT0l3ME22MlMhdk1? NVX0S2ZqOjF5M{e1NFI>
SK-MEL-28 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvHTVUxRTdwNjDuUS=> MX[yNVc{PzVyMh?=
SK-MEL-2 NXq2NVRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDHTVUxRTFzIH7N MoPPNlE4Ozd3MEK=
DB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\nTVQ5yqCq NVvUZZo{T0l3ME2zMlUhdk1? M{X4[lIyOjN5NUC4
Pfeiffer MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVi0POKhcA>? NIfxV5RIUTVyPUOuPUBvVQ>? MlfaNlEzOzd3MEi=
SU-DHL-5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\OU2k1QMLiaB?= M3HxR2dKPTB;MD6yN{BvVQ>? NWf1[FJNOjF{M{e1NFg>
SU-DHL-8 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTJe5QxPDkEoHi= NVqxNYhOT0l3ME2xMlQhdk1? NW\NcYxSOjF{M{e1NFg>
WSU-DLCL-2 NIPY[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\QXVQ5yqCq MkKwS2k2OD1zLkSgcm0> NVHZeGhxOjF{M{e1NFg>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

+ Expand
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Formulation: Dissolved and diluted in saline immediately before administration
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID